Cboe UK EUR
Merck & Co., Inc. (6MKD.XC)
70.20
+2.50
+(3.69%)
As of 8:25:32 AM GMT+1. Market Open.
Research Analysis
Earnings Estimate
Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
---|---|---|---|---|
No. of Analysts | -- | -- | -- | -- |
Avg. Estimate | 0 | 0 | 0 | 0 |
Low Estimate | 0 | 0 | 0 | 0 |
High Estimate | 0 | 0 | 0 | 0 |
Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
---|---|---|---|---|
No. of Analysts | 13 | 12 | 23 | 23 |
Avg. Estimate | 15.87B | 17.16B | 65.14B | 69.1B |
Low Estimate | 15.46B | 16.81B | 64.09B | 66.76B |
High Estimate | 16.27B | 17.44B | 68.2B | 73.6B |
Year Ago Sales | 16.11B | 16.66B | 64.17B | 65.14B |
Sales Growth (year/est) | -1.52% | 2.99% | 1.51% | 6.08% |
EPS Trend
Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
---|---|---|---|---|
Current Estimate | 0 | 0 | 0 | 0 |
7 Days Ago | 0 | 0 | 0 | 0 |
30 Days Ago | 0 | 0 | 0 | 0 |
60 Days Ago | 0 | 0 | 0 | 0 |
90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
---|---|---|---|---|
Up Last 7 Days | -- | -- | -- | -- |
Up Last 30 Days | -- | -- | -- | -- |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
Current Qtr. | Next Qtr. | Current Year | Next Year | |
---|---|---|---|---|
6MKD.XC | -- | -- | -- | -- |
S&P 500 | 6.94% | 4.52% | 8.32% | 14.18% |
Upgrades & Downgrades
Initiated | Cantor Fitzgerald: Neutral | 4/22/2025 |
Reiterates | Guggenheim: Buy to Buy | 4/17/2025 |
Downgrade | Deutsche Bank: Buy to Hold | 2/18/2025 |
Maintains | Guggenheim: Buy to Buy | 2/12/2025 |
Maintains | B of A Securities: Buy to Buy | 2/5/2025 |
Maintains | BMO Capital: Market Perform to Market Perform | 2/5/2025 |